Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-101 in Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin
NCT04673617Phase 2Completed
- Sponsor
- Artiva Biotherapeutics, Inc.
- Start
- Mar 2021
- Primary completion
- Oct 2025
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AlloNK in non-Hodgkin lymphoma (NHL), sponsored by Artiva Biotherapeutics, Inc.. Started Mar 2021; status: completed.
02
Drugs
AlloNK
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04673617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673617.